64
Participants
Start Date
February 1, 2026
Primary Completion Date
June 1, 2027
Study Completion Date
June 30, 2027
Empagliflozin 25 MG plus Pioglitazone placebo
A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
Placebo-Inert tablet
Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Pioglitazone, a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
Pioglitazone placebo + Empagliflozin placebo
Placebo-Inert tablet
RECRUITING
Texas Diabetes Institute/UH, San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
The University of Texas Health Science Center at San Antonio
OTHER